Navigation Links
Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
Date:9/5/2008

The Study Demonstrates microRNAs Extracted From a Simple Blood Draw Have the Potential to Serve as Effective Clinical Biomarkers for a Wide Range of

Indications Using This Proprietary Technology, Rosetta Genomics is Currently Developing

a Blood-Based Test to Detect Colon Cancer

REHOVOT, Israel and JERSEY CITY, New Jersey, September 5 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today that the results of a study conducted by its scientists describing the identification of microRNA biomarkers in blood serum, have been published online in the peer-reviewed journal PLOS One. The findings demonstrate that microRNAs have the potential to be used as clinical biomarkers for a wide range of indications in cancer and women's health.

Using its proprietary extraction and quantification methods, Rosetta Genomics is now advancing the development of a blood-based test which will utilize microRNAs to detect patients with colon cancer.

"This study further validates our understanding that microRNAs may be used as clinical biomarkers for a wide range of indications, both through invasive and non-invasive methods," noted Dr. Dalia Cohen, Chief Scientific Officer of Rosetta Genomics. "The results of this study are the basis of one of our development programs to detect colon cancer via microRNAs identified in serum. I believe our strong scientific capabilities will continue to produce exciting studies, which we will share once available."

The paper, "Serum MicroRNAs are Promising Novel Biomarkers" is now available on PLOS One website on http://dx.plos.org/10.1371/journal.pone.0003148

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators a
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
2. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
3. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
4. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
5. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
6. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2008)...3 Wyeth Pharmaceuticals,...day that it has submitted a,marketing authorizati...ncy,(EMEA) for approval to market its investigati...V13) for infants and young children. Wyeth is see...ccal disease (PD) caused by the 13,serotypes incl...
(Date:12/2/2008)...ire-USNewswire/ -- Researchers using functional,M...e area of the brain,responsible for suppressing m...,stress-related psychiatric disorders. Results of ...eeting of the Radiological Society of North Americ...ssion and other stress-related disorders,traumat...
(Date:12/2/2008)...Newswire/ -- Horizon Therapeutics, Inc., a,privat...d that two pivotal,Phase 3 trials evaluating its ...met all primary endpoints. HZT-501, a novel, propr...ibuprofen and famotidine, demonstrated a,statisti...n-steroidal,anti-inflammatory drug (NSAID)-induce...
(Date:12/1/2008)...swire/ -- TargeGen has announced that an oral,pre...ter, US-based clinical,trial of TG101348 in myelo...at,the 2008 American Society of Hematology (ASH) ...e as follows:, Title: A Phase I... JAK2-Selective Inhibitor, in Pat...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 1Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 2Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 3MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 1MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 2Mounting evidence shows red wine antioxidant kills cancer 2618 1Mounting evidence shows red wine antioxidant kills cancer 2618 2Mounting evidence shows red wine antioxidant kills cancer 2618 3New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 1New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 2
...ne Plus Minocycline Showed Substantial,Reduction o...ng-Remitting Multiple Sclerosis , Combination Trea...s and Was Well Tolerated , KANSAS CITY, Mo, May 4,...tudy showed that a combination of Copaxone,(glatir...otic,minocycline reduced T1 Gadolinium (Gd)-enhanc...
...th May 2007 - CeNeS Pharmaceuticals plc,(LSE: CEN)...otes,the publication of an independent study in th...hase II NMDA antagonist, CNS 5161. CeNeS,is develo...thic,pain. The independent study builds on the wor... , In the study reported in ,Synapse, Dr Anat Bie...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
(Date:12/4/2008)...TIST HEALTH, a six-hospital,system based in Littl...m, has,expanded its use of Clinical Xpert(TM) Car...abled the system,s pharmacists to increase necessa...illion. , "Data we collected for the 220-be...ompts approximately half of the pharmacy clinical ...
(Date:12/4/2008)...study of 491 women with invasive ovarian cancer fo...r genetic testing of BRCA1 and BRCA2, the breast c...formed of their cancer risk. , Dr. Kelly Metcal...ronto,s Lawrence S. Bloomberg Faculty of Nursing, ...ch Institute, led the nursing study, which was pub...
(Date:12/4/2008)... on the eve of its 35th Anniversary, Ronald McDona...d Season of Giving marketing campaign to remind co...itiative, designed to drive personal donations, wi...ree core programs: Ronald McDonald House, Ronald M...obile. , OAK BROOK, III....
(Date:12/4/2008)...en Joffe, Craig Joffe, and,Alan Buckey today file...,Securities and Exchange Commission. The group p...4% of LCA-Vision, Inc. (Nasdaq: LCAV ), which,o...ction centers in 33 states,in the United States. ...CEO of,LCAV. Craig Joffe is the former Chief Ope...
Breaking Medicine News(10 mins):Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6
...l infections with an antibiotic gel reduced the pr...oughout the body,// pointing to further evidence o...ealth, investigators from the University at Buffal.... The investigators divided a sample of 100 adult...
...diation may cause skin cancer, but it also prevent... According to many, UV-B - the solar radiation tha..., and other skin cancers. That is generally true, ...that the reverse may also be the case - that UV-B ...
...icals Ltd today said its newly- found andti-diabet... trials by later this year. Mr Glenn Saldanha, Exe...wspersons that the company’s R&D team has establis... this molecule.// The global diabetes market is e...
...f bypass patients suffer mental decline after bypa...mbering. One leading theory is that the heart-lung...udy,// the loss of mental sharpness suffered by ma...gery may not be caused by the heart-lung machine u...
Other Medicine News:
Large solid mallet with patented Ortho-Grip® silicone rubber handle.
Angled ring curette.
Perisoteal rasp for elevating, dissecting, and scraping.
Stainless steel bone clamp.
Medicine Products: